科伦药业
(002422)
| 流通市值：423.45亿 | | | 总市值：518.92亿 |
| 流通股本：13.07亿 | | | 总股本：16.02亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 6,219,417,413 | 21,453,929,237 | 15,743,097,216 | 10,733,926,609 |
| 营业收入 | 6,219,417,413 | 21,453,929,237 | 15,743,097,216 | 10,733,926,609 |
| 二、营业总成本 | 4,767,842,902 | 18,277,363,122 | 13,469,903,968 | 9,088,100,822 |
| 营业成本 | 2,746,623,888 | 10,205,534,588 | 7,409,716,721 | 5,015,003,406 |
| 税金及附加 | 63,763,665 | 302,726,528 | 232,751,027 | 154,222,843 |
| 销售费用 | 1,101,758,680 | 4,449,718,404 | 3,249,237,667 | 2,179,052,030 |
| 管理费用 | 336,048,506 | 1,142,052,035 | 706,770,112 | 498,169,144 |
| 研发费用 | 502,816,867 | 1,943,570,077 | 1,665,659,341 | 1,075,856,695 |
| 财务费用 | 16,831,296 | 233,761,490 | 205,769,100 | 165,796,704 |
| 其中:利息费用 | 47,635,913 | 361,538,172 | 291,195,563 | 229,860,423 |
| 其中:利息收入 | 22,314,195 | 103,592,175 | 75,907,728 | 48,204,106 |
| 加:公允价值变动收益 | 2,938,945 | 14,666,354 | -87,183 | 3,264,144 |
| 加:投资收益 | 111,835,302 | 358,881,875 | 266,981,025 | 170,496,770 |
| 资产处置收益 | 646,018 | 2,626,645 | 1,906,464 | 1,637,311 |
| 资产减值损失(新) | 0 | -130,550,972 | -46,598,036 | -46,598,036 |
| 信用减值损失(新) | -46,365,589 | -45,984,834 | -77,342,737 | -37,077,927 |
| 其他收益 | 111,819,017 | 277,937,975 | 179,426,495 | 140,017,547 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 1,632,448,204 | 3,654,143,158 | 2,597,479,276 | 1,877,565,596 |
| 加:营业外收入 | 1,693,421 | 11,855,064 | 4,515,413 | 1,939,789 |
| 减:营业外支出 | 9,346,453 | 85,572,172 | 56,199,401 | 26,320,047 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 1,624,795,172 | 3,580,426,050 | 2,545,795,288 | 1,853,185,338 |
| 减:所得税费用 | 338,993,759 | 933,786,688 | 402,765,455 | 275,539,483 |
| 六、净利润 | 1,285,801,413 | 2,646,639,362 | 2,143,029,833 | 1,577,645,855 |
| 持续经营净利润 | 1,285,801,413 | 2,646,639,362 | 2,143,029,833 | 1,577,645,855 |
| 归属于母公司股东的净利润 | 1,026,188,176 | 2,456,112,045 | 1,963,327,343 | 1,402,202,255 |
| 少数股东损益 | 259,613,237 | 190,527,317 | 179,702,490 | 175,443,600 |
| (一)基本每股收益 | 0.67 | 1.69 | 1.35 | 0.97 |
| (二)稀释每股收益 | 0.67 | 1.59 | 1.27 | 0.91 |
| 八、其他综合收益 | -845,212 | -60,842,218 | 73,410,076 | 87,050,521 |
| 归属于母公司股东的其他综合收益 | -1,446,988 | -60,369,779 | 70,759,783 | 84,698,584 |
| 九、综合收益总额 | 1,284,956,201 | 2,585,797,144 | 2,216,439,909 | 1,664,696,376 |
| 归属于母公司股东的综合收益总额 | 1,024,741,188 | 2,395,742,266 | 2,034,087,126 | 1,486,900,839 |
| 归属于少数股东的综合收益总额 | 260,215,013 | 190,054,878 | 182,352,783 | 177,795,537 |
| 公告日期 | 2024-04-25 | 2024-04-25 | 2023-10-31 | 2023-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |